Hi Biotech, can I be outrageously lazy (it's late after all), does that (very good) NICE article relate to standard or high sensitivity troponin testing? Philips might contemplate releasing a lower performance system initially prior to one that can compete with central lab high sensitivity tests. It's also important to realise that sensitivity needs to be high too to have a workable test.
I suspect that ADO can offer advantages on both sides, both in beating the sensitivity levels of the high performing central labs, and in addressing elements that contribute background (e.g. heterophile antibodies).
POC1 have dragged us over the coals long enough but if that's the best they can do they won't have anywhere near the impact needed to dominate the market and reassure a spooked FDA. Obviously I'm pretty desperate for our moment in the spotlight and finally having a platform to show just how impressive M&G can be!
ADO Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held
